

1 **Characterizing the blood stage antimalarial activity of tafenoquine in healthy**
2 **volunteers experimentally infected with *Plasmodium falciparum***

3

4 Bridget E. Barber^{1,2,3^}, Azrin N. Abd-Rahman^{1^}, Rebecca Webster¹, Adam J. Potter¹, Stacey
5 Llewellyn¹, Louise Marquart¹, Nischal Sahai², Indika Leelasena², Geoffrey W. Birrell⁴,
6 Michael D. Edstein⁴, G. Dennis Shanks⁴, David Wesche⁵, Joerg J. Moehrle⁶, James S.
7 McCarthy^{1,7#}

8

9 ¹QIMR Berghofer Medical Research Institute, Brisbane, Australia

10 ²University of the Sunshine Coast, Morayfield, Australia

11 ³Royal Brisbane and Women's Hospital, Brisbane, Australia

12 ⁴Australian Defence Force Malaria and Infectious Disease Institute, Brisbane, Australia

13 ⁵Certara, Michigan, USA

14 ⁶Medicines for Malaria Venture, Geneva, Switzerland

15 ⁷The Peter Doherty Institute for Infection and Immunity, Melbourne, Australia

16

17 [^] Bridget E. Barber and Azrin Abd-Rahman contributed equally to this manuscript.

18

19 ***Corresponding author:** Dr. Bridget E. Barber. QIMR Berghofer Medical Research

20 Institute, 300 Herston Road, Herston 4006, Australia. Email:

21 bridget.barber@qimrberghofer.edu.au. Telephone: +61 7 3362 0498.

22 **#Alternate corresponding author:** Dr. James S. McCarthy. The Peter Doherty Institute for
23 Infection and Immunity, 792 Elizabeth Street, Melbourne 3000, Australia. Email:
24 james.mccarthy@unimelb.edu.au. Telephone: +61 3 8344 0927.

25

26 **Keywords:** *Plasmodium falciparum*, tafenoquine, blood stage, antimalarial.

27

28 **Running title:** Antimalarial activity of tafenoquine.

29

30 **Main point:** A single oral dose of tafenoquine is effective against blood stage *Plasmodium*
31 *falciparum* infection. However, as the estimated dose to clear asexual parasitaemia is ≥ 460
32 mg (in adults), prior screening for glucose 6-phosphate dehydrogenase deficiency will be
33 required.

34

35 Main point word count= 38 (40 max)

36 Abstract word count=248 (250 max)

37 Body text word count= 2947 (3000 max)

38 Reference count = 35 (40 max)

39

40 **ABSTRACT**

41 **Background**

42 The long acting 8-aminoquinoline tafenoquine may be a good candidate for mass drug
43 administration if it exhibits sufficient blood stage antimalarial activity at doses low enough to
44 be tolerated by glucose 6-phosphate dehydrogenase (G6PD) deficient individuals.

45 **Methods**

46 Healthy G6PD-normal adults were inoculated with *Plasmodium falciparum* 3D7-infected
47 erythrocytes on day 0. Different single oral doses of tafenoquine were administered on day 8.
48 Parasitemia, and concentrations of tafenoquine and the 5,6-orthoquinone metabolite in
49 plasma/whole blood/urine were measured and standard safety assessments performed.
50 Curative artemether-lumefantrine therapy was administered if parasite regrowth occurred, or
51 on day 48±2. Outcomes were parasite clearance kinetics, pharmacokinetic and
52 pharmacokinetic/pharmacodynamic (PK/PD) parameters from modelling, and dose
53 simulations in a theoretical endemic population.

54 **Results**

55 Twelve participants were inoculated and administered 200 mg (n=3), 300 mg (n=4), 400 mg
56 (n=2), or 600 mg (n=3) tafenoquine. The parasite clearance half-life with 400 mg or 600 mg
57 (5.4 h and 4.2 h respectively) was faster than with 200 mg or 300 mg (11.8 h and 9.6 h
58 respectively). Parasite regrowth occurred after dosing with 200 mg (3/3 participants) and 300
59 mg (3/4 participants), but not after 400 mg or 600 mg. Simulations using the PK/PD model
60 predicted that 460 mg and 540 mg would clear parasitaemia by a factor of 10⁶ and 10⁹,
61 respectively, in a 60 kg adult.

62 **Conclusions**

63 Although a single dose of tafenoquine exhibits potent *P. falciparum* blood stage antimalarial
64 activity, the estimated doses to effectively clear asexual parasitemia will require prior
65 screening to exclude G6PD deficiency.

66

67 **Abbreviations:** AEs: adverse events; G6PD: glucose 6-phosphate dehydrogenase; IBSM:
68 induced blood stage malaria; MDA: mass drug administration; PK/PD:
69 pharmacokinetic/pharmacodynamics.

70

71 **INTRODUCTION**

72 The global burden of malaria remains high, with an estimated 241 million cases and 627,000
73 deaths in 2020 [1]. The emergence of artemisinin-resistant *Plasmodium falciparum* in
74 Southeast Asia [2], and more recently in East Africa [3], threatens the utility of the current
75 first line artemisinin combination therapies and progress toward malaria eradication. There is
76 growing recognition for the need to treat both asymptomatic and symptomatic malaria
77 infections to reduce the parasite reservoir [4] and to slow the spread of drug-resistant
78 parasites [5]. Mass drug administration (MDA) in endemic populations is one approach to
79 rapidly reduce malaria morbidity and mortality and interrupt transmission. The World Health
80 Organization (WHO) defines malaria MDA as the administration of a full dose of
81 antimalarial treatment to an entire population in a given area, except those in whom the
82 medicine is contraindicated [6]. Further, medicines used for MDA should be of proven
83 efficacy in the implementation area, have a long half-life, and be different to those medicines
84 used for first line treatment [6].

85 The 8-aminoquinoline tafenoquine is a long acting analogue of primaquine that is currently
86 approved for malaria chemoprophylaxis and for radical cure of vivax malaria [7]. The fact
87 that tafenoquine has a very long elimination half-life (approximately 16 days [8]) and broad
88 activity against all parasite lifecycle stages [9], indicates that it may be a suitable candidate
89 for use in MDA. However, although the blood schizonticidal activity of tafenoquine has been
90 established in humans [10, 11], the dose required to clear asexual *P. falciparum* parasites has
91 not yet been determined. Furthermore, as with primaquine, the use of tafenoquine is limited
92 by the risk of hemolysis in glucose-6-phosphate dehydrogenase (G6PD) deficient individuals,
93 and administration of tafenoquine at currently recommended doses (200 mg for
94 chemoprophylaxis and 300 mg for *P. vivax* radical cure) requires prior G6PD testing, which
95 can be costly and logistically difficult in low- and middle-income countries. However, the

96 fact that the hemolytic potential of tafenoquine appears to be dose-dependent [12] suggests
97 that low dose tafenoquine may be safe in G6PD-deficient individuals, in a similar manner to
98 low dose primaquine [13].

99 We hypothesized that if a sufficiently low effective dose of tafenoquine was identified, this
100 might allow tafenoquine to be used for MDA in endemic populations, without the need for
101 G6PD testing prior to administration. The purpose of the current study was to use the induced
102 blood stage malaria (IBSM) model to determine the minimum single oral dose of tafenoquine
103 required to effectively clear asexual blood stage *P. falciparum*.

104 **METHODS**

105 **Study design and participants**

106 This was an open label, randomized, clinical trial using the IBSM model. Healthy malaria
107 naïve males and females (non-pregnant, non-lactating) aged 18-55 years were eligible for
108 inclusion (Text S2). All participants were required to have normal G6PD activity at screening
109 (normal range 7.0-20.5 U/g hemoglobin). The study was conducted at the University of the
110 Sunshine Coast Clinical Trials Unit (Morayfield, Australia) and was registered on the
111 Australian and New Zealand Clinical Trials Registry (ACTRN12620000995976).

112 This study was approved by the QIMR Berghofer Medical Research Institute Human
113 Research Ethics Committee (P3646) with mutual recognition by the Australian Departments
114 of Defence and Veterans' Affairs Human Research Ethics Committee (194-19). All
115 participants gave written informed consent before enrollment.

116 **Procedures**

117 Participants were inoculated intravenously with approximately 2800 viable *P. falciparum*
118 3D7 infected erythrocytes on day 0 [14]. Parasitemia was monitored throughout the study by
119 quantitative PCR (qPCR) targeting the gene encoding *P. falciparum* 18S rRNA [15]. A single

120 oral dose of tafenoquine (Kodatef[®], Bioclect) was administered on day 8. All participants in
121 cohort 1 received the same tafenoquine dose (300 mg), with no randomization performed.
122 Participants in cohorts 2 and 3 were randomized to a dose group on day 8. The randomization
123 schedule was generated using STATA 15. No blinding was performed.

124 Plasma, venous and capillary whole blood, and urine concentrations of tafenoquine (and the
125 5, 6-orthoquinone metabolite) were measured by liquid chromatography tandem mass
126 spectrometry [16]. Participants received a curative course of artemether-lumefantrine
127 (Riamet[®], Novartis Pharmaceuticals) if parasite regrowth was detected or on day 48±2.
128 Safety assessments, including monitoring of adverse events (AEs), vital signs, hematology
129 and biochemistry, physical examination, and electrocardiographs, were performed throughout
130 the study.

131 **Outcomes and Statistical analysis**

132 Analysis of parasite clearance kinetics following tafenoquine was performed in R 3.5.0 and
133 RStudio 1.1.447. The parasite reduction ratio over a 48 h period (PRR₄₈) and parasite
134 clearance half-life (PC_{t_{1/2}}) were estimated using the slope of the optimal fit for the log-linear
135 relationship of the parasitemia decay [17]. Non-compartmental pharmacokinetic analysis was
136 performed using PKanalix 2019R1 (Lixoft).

137 Pharmacokinetic (PK) and pharmacokinetic/pharmacodynamic (PK/PD) modelling, and
138 simulations were conducted within R 3.6.3 combined to the IQRtools package 1.7.2 and
139 MonolixSuite 2019R1 (Text S1). PK/PD analyses were performed using non-linear mixed
140 effects models. A population PK model was developed to obtain individual PK parameter
141 estimates that adequately described the observed individual PK profiles. The PK/PD model
142 was then built using the individual PK parameter estimates as regression parameters. Key
143 efficacy parameters including the minimum inhibitory concentration (MIC) and the minimal

144 parasiticidal concentration that achieved 90% of the maximum effect (MPC_{90}) were derived
145 from the final PK/PD model.

146 Simulations were performed in a theoretical endemic population to predict the dose of
147 tafenoquine that would clear parasitemia by a factor of 10^6 and 10^9 in all patients, and
148 achieve adequate parasitological response on day 42 (APR_{42}) with 90% probability (Text S1).
149 Population parameters were sampled from the uncertainty distribution, and individual
150 parameters were sampled from the inter-individual variability (variability of E_{max} was
151 assumed to be 20%). Single doses of 1 to 40 mg/kg tafenoquine (with an increment of 1
152 mg/kg) were simulated in 20 trials of 100 patients each with body weight of 5, 10, 15, 20, 30,
153 40, 50 and 60 kg. Baseline parasitemia was assumed to be log-normally distributed around a
154 median of 10^7 parasites/mL, with inter-individual variability of 60% [18]. The PK and PK/PD
155 relationship were assumed to be the same in patients as in the volunteers, and parasites were
156 assumed to grow exponentially in patients at a growth rate of 0.048 h^{-1} (equivalent to a
157 multiplication rate of approximately 10-fold per asexual cycle of 48 hours) [19, 20].

158 **RESULTS**

159 **Participants**

160 The study was conducted from 27 October 2020 to 09 April 2021. Twelve participants were
161 enrolled across three cohorts (Figure 1). Participants were healthy malaria-naïve males ($n=6$)
162 or females ($n=6$) aged 19 to 53 years (Table 1). All 3 participants in cohort 1 received 300 mg
163 tafenoquine while participants in cohorts 2 and 3 were randomized to a dose group (200 mg,
164 $n=3$; 300 mg, $n=1$; 400 mg, $n=2$; or 600 mg, $n=3$). Doses were selected following review of
165 interim data to optimally characterize the PK/PD relationship. All participants received the
166 allocated treatment, completed the study and were included in the analysis of study
167 endpoints.

168 **Parasite clearance kinetics and regrowth**

169 The progression of parasitemia following intravenous inoculation was consistent between
170 participants up to day 8, when a single oral dose of tafenoquine was administered (Figure 2).
171 An initial reduction in parasitemia occurred in all participants following tafenoquine, with a
172 trend of an increased rate of parasite clearance with increasing dose of tafenoquine (Table 2).
173 Parasite regrowth occurred after dosing with 200 mg (3/3 participants; 8-22 days post-dose)
174 and 300 mg (3/4 participants; 18-27 days post-dose) tafenoquine but not after dosing with
175 400 mg or 600 mg tafenoquine up to day 48 when definitive antimalarial treatment with
176 artemether-lumefantrine was initiated (Figure 2).

177 **Tafenoquine exposure**

178 Dose-related increases in tafenoquine exposure (maximum concentration [C_{max}] and area
179 under the concentration-time curve from time 0 to the last measured time point [AUC_{0-last}])
180 were observed across the dose range (Table 3). Absorption was relatively slow, with time to
181 maximum concentration (t_{max}) approximately 12 h, while a long plasma elimination half-life
182 ($t_{1/2}$) of approximately 13 days was observed. Compared to plasma, venous whole blood
183 tafenoquine exposure (C_{max} and AUC_{0-last}) was higher across the dose range, while t_{max} and
184 $t_{1/2}$ were comparable (Table 3). Concentrations of the 5,6-orthoquinone metabolite were
185 considerably lower than the parent compound in plasma (Figure S1), venous whole blood
186 (Figure S2), and capillary whole blood (Figure S3), but substantially higher in urine (Figure
187 S4).

188 **Pharmacokinetic/Pharmacodynamic analysis**

189 The PK of tafenoquine and 5,6-orthoquinone tafenoquine was described by a mammillary
190 physiological model comprising seven disposition compartments (plasma, red blood cell and
191 urine for both tafenoquine and 5,6-orthoquinone, and an additional tissue compartment for

192 tafenoquine) with first-order absorption and linear elimination (Figure S5 and Table S1).
193 Modelling identified time-dependent parasitemia as a significant covariate on tafenoquine
194 clearance, resulting in decreasing clearance with increasing parasitemia. Visual predictive
195 checks demonstrated that the observed profiles of tafenoquine fit well within the 5th and 95th
196 percentiles of the simulated predictions, indicating the model adequacy in characterizing the
197 observed data (Figure S6).

198 The relationship between tafenoquine red blood cell concentrations and parasite killing was
199 described by an E_{\max} PK/PD model. Modelling was unable to identify a significant
200 relationship between 5,6-orthoquinone concentrations and parasite killing. Population PD
201 parameters (Table S2) were estimated with satisfactory precision (relative standard error
202 <30%). The inter-individual variability in the parasite growth rate constant was estimated
203 with low precision and thus fixed to 0.07 based on retrospective *P. falciparum* parasite
204 growth modelling in IBSM studies. Visual predictive checks demonstrated that the 5th, 50th
205 and 95th percentiles of the observed data were within the 95% CI of the simulated data
206 (Figure S7). PK/PD modelling using population estimates predicted an MIC of 74 ng/mL
207 (0.16 nmol/mL) and a MPC₉₀ of 561 ng/mL (1.21 nmol/mL) (Table S3 and Table S4).

208 **Tafenoquine dose predictions**

209 The single doses of tafenoquine required to clear parasitaemia by a factor of 10^6 and 10^9 , and
210 to achieve APR₄₂ with 90% probability, in all patients within a hypothetical endemic
211 population was predicted using the PK/PD model with the associated inter-individual
212 variability, covariate effect and model parameter uncertainty. Analyses were performed using
213 body weights ranging from 5 to 60 kg, and baseline parasitemia log-normally distributed
214 around a median of 10^7 parasites/mL (inter-individual variability 60%), to simulate dosing an
215 entire endemic population in the context of MDA. The predicted dose required to clear

216 parasitemia by a factor of 10^6 ranged from 50 mg (10 mg/kg) for a 5 kg infant to 460 mg (7.7
217 mg/kg) for a 60 kg adult (Table 4). Higher doses were predicted to be required to clear
218 parasitemia by a factor of 10^9 (eg. 65 mg for a 5 kg infant and 540 mg for a 60 kg adult), and
219 to achieve APR_{42} (Table 4).

220 **Safety and tolerability**

221 A total of 160 AEs were reported, the majority (102/160) being mild to moderate signs and
222 symptoms of malaria (Table 5). No AEs met the criteria of a serious adverse event or resulted
223 in a participant discontinuing the study. There were 39 AEs considered related to tafenoquine
224 (Table S5), with an increase in blood methemoglobin above the upper limit of normal (1.2%)
225 the most commonly reported (10/12 participants). The peak methemoglobin concentration
226 was related to the dose of tafenoquine administered, with 400 or 600 mg doses resulting in a
227 greater elevation (2-5% at peak) compared to 200 or 300 mg doses (<2% at peak) (Figure
228 S11). Blood methemoglobin AUC_{0-last} and C_{max} correlated with the AUC_{0-last} and C_{max} of
229 tafenoquine and 5,6-orthoquinone in whole blood and plasma (Figures S12 and S13). The
230 methemoglobin elevations were not accompanied by signs and symptoms associated with
231 methemoglobinemia. A mild decrease in hemoglobin from baseline (pre-malaria inoculation)
232 was recorded for 3 participants (largest decrease 24 g/L). Overall, hemoglobin concentrations
233 did not appear to be dose related (Figure S10).

234 **DISCUSSION**

235 The objective of this study was to characterize the blood stage *P. falciparum* antimalarial
236 activity of tafenoquine in humans, with a view to potentially expanding the utility of the drug
237 beyond its current indications of malaria prophylaxis and radical cure of vivax malaria. The
238 fact that tafenoquine has a very long elimination half-life and exhibits activity against
239 multiple parasite lifecycle stages, including the asexual blood stage [10, 11] and gametocytes
240 responsible for transmission [21-23], indicated that it may be an appropriate candidate for

241 MDA. The use of medicines with demonstrated efficacy for treatment, at full treatment doses,
242 is important for MDA because some of the individuals treated will be parasitemic. It has been
243 suggested that, at minimum, antimalarial drugs intended to clear asexual blood-stage
244 parasitemia should clear parasites at least as fast as mefloquine, and reduce parasitemia by a
245 factor of at least 10^6 [24]. These properties served as benchmarks for our evaluation of
246 tafenoquine.

247 The rate of parasite clearance with 400 mg or 600 mg tafenoquine ($PC_{t_{1/2}}$ 5.4 h and 4.2 h
248 respectively) was faster than that previously characterized for 10 mg/kg mefloquine ($PC_{t_{1/2}}$
249 6.2 h) using the IBSM model [25]. Doses of 200 mg or 300 mg tafenoquine were associated
250 with a considerably slower rate of parasite clearance ($PC_{t_{1/2}}$ 11.8 h and 9.6 h respectively).
251 Dose simulations in an endemic population took into account the higher parasite burdens, and
252 greater variability in baseline parasitemia, compared to the volunteers in the current study.
253 This was particularly important given that PK modelling revealed that higher parasitemia was
254 associated with greater tafenoquine exposure due to reduced clearance. Adult doses of 460
255 mg (7.7 mg/kg) and 540 mg (9 mg/kg) were predicted to clear parasitemia by a factor of 10^6
256 and 10^9 respectively, while 960 mg (16 mg/kg) would achieve APR_{42} with 90% probability.
257 The estimation of APR_{42} was considered informative albeit not entirely relevant for MDA,
258 given that in practice all curative antimalarial treatments consist of combinations of two or
259 more drugs, and/or require multiple doses.

260 The adult dose of tafenoquine predicted to clear asexual *P. falciparum* parasitaemia is higher
261 than the dose currently recommended for preventing *P. vivax* relapse (300 mg), although it
262 has recently been proposed that higher doses may be required to improve the effectiveness of
263 anti-relapse treatment [26]. There is increased risk of *P. vivax* parasitemia following
264 treatment of falciparum malaria in areas that are co-endemic for both species, and thus a
265 rationale exists for administration of a radically curative treatment to patients with *P.*

266 *falciparum*, even in the absence of detectable *P. vivax* [27]. Thus, the use of tafenoquine at
267 the dose predicted to clear falciparum parasitaemia would likely also be beneficial in
268 reducing the incidence of *P. vivax* relapse.

269 Although the results of this study indicate that tafenoquine exhibits potent blood stage
270 antimalarial activity, the estimated doses required to clear asexual parasitemia will require
271 prior screening for G6PD activity. A specific dose of tafenoquine that could be safely
272 administered to G6PD-deficient individuals has not been established. However, a dose of 300
273 mg was found to result in a hemoglobin drop >2.5 g/dL in a small group of G6PD
274 heterozygous adult females with enzyme activity 40-60% of normal [12]. Thus, it seems
275 unlikely that the predicted doses required to clear asexual parasitemia could be safely
276 administered for this purpose in the context of MDA. However, we and others have
277 demonstrated that single low doses of tafenoquine (<100 mg adult dose) can reduce the
278 transmission of *P. falciparum* to mosquitoes [22, 23]. Thus, the use of tafenoquine for this
279 purpose, in combination with a partner drug to clear asexual parasitaemia, may be worthy of
280 investigation for MDA.

281 As expected, no significant safety signals were associated with tafenoquine dosing of
282 volunteers with normal G6PD levels in the current study. A mild transient decrease in
283 hemoglobin occurred in a few participants, although this did not appear to be dose related and
284 has been observed previously with blood stage malaria challenge of healthy volunteers [28].
285 A dose related transient increase in blood methemoglobin was observed, without clinical
286 symptoms associated with methemoglobinemia. Similar observations have been reported
287 following tafenoquine dosing of patients with *vivax* malaria [29-31]. The production of dose-
288 dependent methemoglobinemia by 8-aminoquinoline antimalarials is associated with their
289 efficacy against latent *P. vivax* and *P. ovale* [32]. The results of our study suggest that a
290 similar phenomenon may exist for tafenoquine activity against asexual blood stage *P.*

291 *falciparum*. Doses of 400 or 600 mg resulted in a notably greater elevation in methemoglobin
292 compared to doses of 200 or 300 mg, while also resulting in faster parasite clearance without
293 subsequent parasite regrowth. The specific mechanisms of tafenoquine-induced parasite
294 killing, hemolytic toxicity, and methemoglobinemia remain unclear. It is hypothesized that
295 tafenoquine exhibits parasite stage-specific activity associated with different metabolites and
296 different modes of action [33]. Activity against blood stage parasites is thought to be
297 independent of CYP-2D6 metabolism, potentially involving interference with heme
298 polymerization, or oxidative mechanisms [33]. The 5,6-orthoquinone metabolite of
299 primaquine is considered a surrogate marker for active metabolites of primaquine [34].
300 Although we were able to measure the 5,6-orthoquinone metabolite of tafenoquine, a
301 relationship between the concentration of this metabolite and parasite killing was not
302 observed. Further work to better understand the role of the metabolite and the mode of action
303 of tafenoquine is warranted.

304 The primary limitation of this study is that the predicted doses required to clear parasitemia in
305 an endemic population were based on the assumption that the PK/PD relationship
306 characterized in the volunteers would be the same in the target population. We cannot
307 discount the possibility that the PK/PD relationship between tafenoquine and parasite killing
308 would be influenced by other factors such as host immunity, G6PD activity, and other
309 bioactive metabolites. However, estimates of therapeutic doses of other antimalarial drugs in
310 volunteers has translated well to patient populations [25, 35].

311 In conclusion, this study has demonstrated that tafenoquine exhibits potent *P. falciparum*
312 blood stage antimalarial activity in humans when administered as a single dose. However, the
313 predicted doses required to clear asexual parasitemia will require prior screening for G6PD
314 activity. This would limit its use for the purpose of clearing asexual parasitaemia in MDA
315 where widespread G6PD screening would prove costly and logistically difficult.

316 **FUNDING**

317 This study was funded by the Bill and Melinda Gates Foundation (INV-001965). Additional
318 funding support was provided to the Clinical Malaria Group within QIMR Berghofer Medical
319 Research Institute by Medicines for Malaria Venture.

320 **CONFLICTS OF INTEREST**

321 BEB and JSM declare receipt of funding from the Bill and Melinda Gates Foundation and
322 Medicines for Malaria Venture (MMV). GDS declares participation on an Expert Scientific
323 Advisory Committee for MMV and participation on Data Safety Monitoring Boards for
324 multiple MMV sponsored clinical trials. All other authors declare no conflicts of interest.

325 **ACKNOWLEDGEMENTS**

326 We thank all the volunteers who participated in the study, staff at the University of the
327 Sunshine Coast Clinical Trials Unit who conducted the trial, staff at the Queensland
328 Paediatric Infectious Diseases laboratory for qPCR analysis, Dr. Scott Miller from the Bill
329 and Melinda Gates Foundation for valuable discussions as part of the Safety and Data Review
330 Team, and Karin Van Breda from the Australian Defence Force Malaria and Infectious
331 Disease Institute for the measurement of tafenoquine concentrations in biospecimens.

332 **DISCLAIMER**

333 The views expressed in this article are those of the authors and do not necessarily reflect the
334 official policy or position of the Australian Defence Force, Joint Health Command or any
335 extant Australian Defence Force policy.

336 **REFERENCES**

- 337 1. World Malaria Report. Geneva: World Health Organization, **2020**.
- 338 2. Ashley EA, Dhorda M, Fairhurst RM, et al. Spread of artemisinin resistance in
339 *Plasmodium falciparum* malaria. N Engl J Med **2014**; 371(5): 411-23.

- 340 3. White NJ. Emergence of artemisinin-resistant *Plasmodium falciparum* in East Africa.
341 N Engl J Med **2021**; 385(13): 1231-2.
- 342 4. Chen I, Clarke SE, Gosling R, et al. "Asymptomatic" malaria: a chronic and
343 debilitating infection that should be treated. PLoS Med **2016**; 13(1): e1001942.
- 344 5. White NJ. Does antimalarial mass drug administration increase or decrease the risk of
345 resistance? Lancet Infect Dis **2017**; 17(1): e15-e20.
- 346 6. The role of mass drug administration, mass screening and treatment, and focal
347 screening and treatment for malaria. World Health Organization, **2015**.
- 348 7. Frampton JE. Tafenoquine: first global approval. Drugs **2018**; 78(14): 1517-23.
- 349 8. Edstein MD, Kocisko DA, Brewer TG, Walsh DS, Eamsila C, Charles BG.
350 Population pharmacokinetics of the new antimalarial agent tafenoquine in Thai
351 soldiers. Br J Clin Pharmacol **2001**; 52(6): 663-70.
- 352 9. Lu KY, Derbyshire ER. Tafenoquine: a step toward malaria elimination.
353 Biochemistry **2020**; 59(8): 911-20.
- 354 10. Dow G, Smith B. The blood schizonticidal activity of tafenoquine makes an essential
355 contribution to its prophylactic efficacy in nonimmune subjects at the intended dose
356 (200 mg). Malar J **2017**; 16(1): 209.
- 357 11. McCarthy JS, Smith B, Reid M, et al. Blood schizonticidal activity and safety of
358 tafenoquine when administered as chemoprophylaxis to healthy, non-immune
359 participants followed by blood stage *Plasmodium falciparum* challenge: a
360 randomized, double-blinded, placebo-controlled phase 1b study. Clin Infect Dis **2019**;
361 69(3): 480-6.
- 362 12. Rueangweerayut R, Bancone G, Harrell EJ, et al. Hemolytic potential of tafenoquine
363 in female volunteers heterozygous for glucose-6-phosphate dehydrogenase (G6PD)

- 364 deficiency (G6PD Mahidol variant) versus G6PD-normal volunteers. *Am J Trop Med*
365 *Hyg* **2017**; 97(3): 702-11.
- 366 13. Bancone G, Chowwiwat N, Somsakchaicharoen R, et al. Single low dose primaquine
367 (0.25 mg/kg) does not cause clinically significant haemolysis in G6PD deficient
368 subjects. *PLoS One* **2016**; 11(3): e0151898.
- 369 14. McCarthy JS, Sekuloski S, Griffin PM, et al. A pilot randomised trial of induced
370 blood-stage *Plasmodium falciparum* infections in healthy volunteers for testing
371 efficacy of new antimalarial drugs. *PLoS One* **2011**; 6(8): e21914.
- 372 15. Rockett RJ, Tozer SJ, Peatey C, et al. A real-time, quantitative PCR method using
373 hydrolysis probes for the monitoring of *Plasmodium falciparum* load in
374 experimentally infected human volunteers. *Malar J* **2011**; 10(1): 1-6.
- 375 16. Birrell GW, Van Breda K, Barber BE, et al. Quantification of tafenoquine and 5,6-
376 orthoquinone tafenoquine by UHPLC-MS/MS in blood, plasma, and urine, and
377 application to a pharmacokinetic study. *Molecules* **2022**; In Press.
- 378 17. Marquart L, Baker M, O'Rourke P, McCarthy JS. Evaluating the pharmacodynamic
379 effect of antimalarial drugs in clinical trials by quantitative PCR. *Antimicrob Agents*
380 *Chemother* **2015**; 59(7): 4249-59.
- 381 18. Phyto AP, Jittamala P, Nosten FH, et al. Antimalarial activity of artefenomel (OZ439),
382 a novel synthetic antimalarial endoperoxide, in patients with *Plasmodium falciparum*
383 and *Plasmodium vivax* malaria: an open-label phase 2 trial. *Lancet Infect Dis* **2016**;
384 16(1): 61-9.
- 385 19. Dietz K, Raddatz G, Molineaux L. Mathematical model of the first wave of
386 *Plasmodium falciparum* asexual parasitemia in non-immune and vaccinated
387 individuals. *Am J Trop Med Hyg* **2006**; 75(2 Suppl): 46-55.

- 388 20. Simpson JA, Aarons L, Collins WE, Jeffery GM, White NJ. Population dynamics of
389 untreated *Plasmodium falciparum* malaria within the adult human host during the
390 expansion phase of the infection. *Parasitology* **2002**; 124(Pt 3): 247-63.
- 391 21. Coleman RE, Clavin AM, Milhous WK. Gametocytocidal and sporontocidal activity
392 of antimalarials against *Plasmodium berghei* ANKA in ICR Mice and *Anopheles*
393 *stephensi* mosquitoes. *Am J Trop Med Hyg* **1992**; 46(2): 169-82.
- 394 22. Stone W, Mahamar A, Smit MJ, et al. Single low-dose tafenoquine combined with
395 dihydroartemisinin-piperaquine to reduce *Plasmodium falciparum* transmission in
396 Ouelessebouyou, Mali: a phase 2, single-blind, randomised clinical trial. *Lancet*
397 *Microbe* **2022**; 3(5): e336-e47.
- 398 23. Webster R, Mitchell H, Peters JM, et al. Transmission blocking activity of low dose
399 tafenoquine in healthy volunteers experimentally infected with *Plasmodium*
400 *falciparum*. *Clin Infect Dis* **2022**; ciac503.
- 401 24. Burrows JN, Duparc S, Gutteridge WE, et al. New developments in anti-malarial
402 target candidate and product profiles. *Malar J* **2017**; 16(1): 26.
- 403 25. McCarthy JS, Lotharius J, Ruckle T, et al. Safety, tolerability, pharmacokinetics, and
404 activity of the novel long-acting antimalarial DSM265: a two-part first-in-human
405 phase 1a/1b randomised study. *Lancet Infect Dis* **2017**; 17(6): 626-35.
- 406 26. Watson JA, Nekkab N, White M. Tafenoquine for the prevention of *Plasmodium*
407 *vivax* malaria relapse. *Lancet Microbe* **2021**; 2(5): e175-e6.
- 408 27. Hossain MS, Commons RJ, Douglas NM, et al. The risk of *Plasmodium vivax*
409 parasitaemia after *P. falciparum* malaria: An individual patient data meta-analysis
410 from the WorldWide Antimalarial Resistance Network. *PLoS Med* **2020**; 17(11):
411 e1003393.

- 412 28. Woolley SD, Marquart L, Woodford J, et al. Haematological response in experimental
413 human *Plasmodium falciparum* and *Plasmodium vivax* malaria. *Malar J* **2021**; 20(1):
414 470.
- 415 29. Fukuda MM, Krudsood S, Mohamed K, et al. A randomized, double-blind, active-
416 control trial to evaluate the efficacy and safety of a three day course of tafenoquine
417 monotherapy for the treatment of *Plasmodium vivax* malaria. *PLoS One* **2017**; 12(11):
418 e0187376.
- 419 30. Walsh DS, Looareesuwan S, Wilairatana P, et al. Randomized dose-ranging study of
420 the safety and efficacy of WR 238605 (Tafenoquine) in the prevention of relapse of
421 *Plasmodium vivax* malaria in Thailand. *J Infect Dis* **1999**; 180(4): 1282-7.
- 422 31. Walsh DS, Wilairatana P, Tang DB, et al. Randomized trial of 3-dose regimens of
423 tafenoquine (WR238605) versus low-dose primaquine for preventing *Plasmodium*
424 *vivax* malaria relapse. *Clin Infect Dis* **2004**; 39(8): 1095-103.
- 425 32. White NJ, Watson JA, Baird JK. Methaemoglobinaemia and the radical curative
426 efficacy of 8-aminoquinoline antimalarials. *Br J Clin Pharmacol* **2022**; 88(6): 2657-
427 64.
- 428 33. Hounkpatin AB, Kreidenweiss A, Held J. Clinical utility of tafenoquine in the
429 prevention of relapse of *Plasmodium vivax* malaria: a review on the mode of action
430 and emerging trial data. *Infect Drug Resist* **2019**; 12: 553-70.
- 431 34. Vanachayangkul P, Sea D, Wojnarski M, et al. Measurements of 5,6-orthoquinone, a
432 surrogate for the presumed active primaquine metabolite 5-hydroxyprimaquine, in the
433 urine of Cambodian adults. *Antimicrob Agents Chemother* **2022**; 66(3): e0182121.
- 434 35. Llanos-Cuentas A, Casapia M, Chuquiyauri R, et al. Antimalarial activity of single-
435 dose DSM265, a novel plasmodium dihydroorotate dehydrogenase inhibitor, in
436 patients with uncomplicated *Plasmodium falciparum* or *Plasmodium vivax* malaria

437 infection: a proof-of-concept, open-label, phase 2a study. *Lancet Infect Dis* **2018**;

438 18(8): 874-83.

439

440

441 **TABLES**

442 **Table 1. Demographic profile of participants.**

		Tafenoquine 200 mg (N=3)	Tafenoquine 300 mg (N=4)	Tafenoquine 400 mg (N=2)	Tafenoquine 600 mg (N=3)	Total (N=12)
Sex [n (%)]	Female	1 (33)	3 (75)	2 (100)	0 (0)	6 (50)
	Male	2 (67)	1 (25)	0 (0)	3 (100)	6 (50)
Race [n (%)]	White	2 (67)	4 (100)	2 (100)	3 (100)	11 (92)
	Asian	1 (33)	0 (0)	0 (0)	0 (0)	1 (8)
Age [years]	Median (range)	40 (28 - 53)	34 (20 - 45)	31 (20 - 41)	23 (19 - 23)	30 (19 - 53)
Body weight [kg]	Median (range)	87 (61 - 95)	81 (71 - 108)	52 (51 - 53)	67 (65 - 100)	72 (51 - 108)
Body mass index [kg/m ²]	Median (range)	29 (26 - 30)	27 (27 - 31)	20 (20 - 21)	21 (20 - 30)	27 (20 - 31)

443

444

445 **Table 2. Parasite clearance parameters following single dose tafenoquine administration to healthy volunteers with induced *P.***
 446 ***falciparum* parasitemia.**

	Tafenoquine 200 mg (N=3^a)	Tafenoquine 300 mg (N=4)	Tafenoquine 400 mg (N=2)	Tafenoquine 600 mg (N=3)
Log ₁₀ PRR ₄₈ (95% CI)	1.23 (1.12 - 1.33)	1.51 (1.41 - 1.61)	2.68 (2.46 - 2.89)	3.42 (3.20 - 3.64)
PCT _{1/2} [h (95% CI)]	11.77 (10.84 - 12.87)	9.57 (8.96 - 10.27)	5.40 (5.00 - 5.87)	4.23 (3.97 - 4.51)
Parasite regrowth incidence [n (%)]	3 (100)	3 (75)	0 (0)	0 (0)

447 Log₁₀PRR₄₈: logarithm to base 10 of the parasite reduction ratio over a 48-hour period; PCT_{1/2}: parasite clearance half-life. ^aOne participant dosed with 200 mg tafenoquine
 448 had a non-significant regression fit and was therefore omitted from the PRR₄₈ and PCT_{1/2} estimates.

449 **Table 3. Tafenoquine plasma and venous whole blood non-compartmental pharmacokinetic parameters associated with single dose**
 450 **administration to healthy volunteers with induced *P. falciparum* parasitemia.**

	Tafenoquine 200 mg (N=3)		Tafenoquine 300 mg (N=4)		Tafenoquine 400 mg (N=2)		Tafenoquine 600 mg (N=3)	
	Plasma	Whole blood	Plasma	Whole blood	Plasma	Whole blood	Plasma	Whole blood
C_{\max} (ng/mL)	138.2 (24.7)	146.5 (40.9)	205.8 (25.6)	242.5 (30.2)	324.8 (21.7)	489.6 (24.1)	340.2 (24.6)	476.8 (35.3)
t_{\max} (h)	12.2 (12.1 - 24.0)	12.2 (12.1 - 48.1)	12.0 (8.1 - 24.0)	12.0 (8.0 - 12.0)	10.0 (8.1 - 12.0)	8.0 (8.0 - 8.1)	12.1 (12.0 - 24.2)	12.0 (8.0 - 24.2)
$AUC_{0-\text{last}}$ (h*ng/mL)	47091 (9.2)	53552 (17.0)	67303 (33.4)	83531 (28.4)	117107 (25.0)	158573 (22.5)	128140 (28.2)	157541 (33.7)
$t_{1/2}$ (h)	309.4 (17.7)	333.3 (5.0)	357.3 (10.3)	302.2 (14.2)	313.9 (13.5)	344.5 (14.6)	314.4 (14.0)	327.0 (4.7)
CL/F (L/h)	3.8 (7.4)	3.3 (13.6)	3.9 (33.7)	3.2 (26.9)	3.1 (29.2)	2.2 (26.5)	4.1 (29.9)	3.4 (33.4)
V_z/F (L)	1708 (22.0)	1585 (18.2)	2003 (33.5)	1378 (34.0)	1379 (15.2)	1109 (11.6)	1863 (24.6)	1585 (30.8)

451 Data are geometric means (coefficient of variation [%]) except t_{\max} which is median (range). C_{\max} : maximum observed concentration; t_{\max} : time to reach the maximum
 452 observed concentration; $AUC_{0-\text{last}}$: area under the concentration-time curve from time 0 (dosing) to the last sampling time at which the concentration is at or above the lower
 453 limit of quantification; $t_{1/2}$: apparent terminal half-life; CL/F: apparent total clearance; V_z/F : apparent volume of distribution.

454 **Table 4. Predicted single doses of tafenoquine required to clear asexual *P. falciparum* parasitemia in all patients within a hypothetical**
 455 **endemic population.**

Body weight (kg)	Dose to clear parasitemia by a factor of		Dose to achieve APR ₄₂ with 90% probability (mg) [mg/kg]
	10 ⁶ (mg) [mg/kg]	10 ⁹ (mg) [mg/kg]	
5	50 [10]	65 [13]	90 [18]
10	95 [9.5]	120 [12]	170 [17]
15	140 [9.3]	170 [11.3]	260 [17.3]
20	170 [8.5]	210 [10.5]	340 [17]
30	250 [8.3]	300 [10]	480 [16]
40	320 [8]	380 [9.5]	640 [16]
50	390 [7.8]	460 [9.2]	780 [15.6]
60	460 [7.7]	540 [9]	960 [16]

456 Single doses of 1 to 40 mg/kg tafenoquine, with an increment of 1 mg/kg, were simulated in 20 trials of 100 patients with each body weight. Simulations were performed
 457 using the pharmacokinetic/pharmacodynamic model developed from the data obtained in healthy volunteers with induced blood stage *P. falciparum*. APR₄₂: adequate
 458 parasitological response on day 42, defined as a decrease in parasitemia below 1 parasite in the body (or below the lower limit of quantification [LLOQ]) within 42 days,
 459 without early treatment failure (parasitemia above baseline at day 2 or above 25% of baseline at day 3) or late clinical failure (parasitemia above the LLOQ after Day 4).

460 **Table 5. Summary of adverse events.**

AE category ^a	Tafenoquine 200 mg (N=3)	Tafenoquine 300 mg (N=4)	Tafenoquine 400 mg (N=2)	Tafenoquine 600 mg (N=3)	Total (N=12)
	Number of participants with at least one AE (%); total number of AEs				
Any AE	3 (100); 39	4 (100); 74	2 (100); 22	3 (100); 25	12 (100); 160
AE related to malaria	3 (100); 24	4 (100); 61	2 (100); 6	3 (100); 11	12 (100); 102
AE related to tafenoquine ^b	3 (100); 9	4 (100); 15	2 (100); 5	3 (100); 10	12 (100); 39
Grade 2 ^c AE	3 (100); 11	4 (100); 18	2 (100); 5	3 (100); 12	12 (100); 46
Grade 2 ^c AE related to tafenoquine	3 (100); 6	3 (75.0); 5	2 (100); 3	3 (100); 8	11 (91.7); 22
Grade 3 ^c AE	2 (66.7); 2 ^d	1 (25.0); 1 ^d	0 (0); 0	0 (0); 0	3 (25.0); 3 ^d

461 Adverse events (AEs) were recorded from administration of the malaria challenge agent until the end of the study. The investigator assessed the relatedness of all adverse
 462 events to tafenoquine, malaria, and artemether-lumefantrine (related or unrelated). Adverse events may have been considered related to more than one study intervention.
 463 ^aNone of the adverse events met the pre-defined criteria for a Serious Adverse Event or resulted in a participant discontinuing the study. ^bAdverse events related to
 464 tafenoquine are specified in Table S5. ^cThe medical assessment of adverse event severity was recorded in accordance with the Common Terminology Criteria for Adverse
 465 Events v5.0, published 27 November 2017 (mild=grade 1; moderate=grade 2; severe=grade 3; potentially life-threatening=grade 4; death related to AE= grade 5). No grade 4
 466 or grade 5 adverse events were recorded. ^dThe grade 3 AEs were a transient decrease in neutrophil count ($0.7 \times 10^9/L$ [normal range $2.0 \square 7.5 \times 10^9/L$]) in one participant (200 mg group) and a
 467 transient decrease in lymphocyte count ($0.4 \times 10^9/L$ [normal range $1.1 \square 4 \times 10^9/L$]) in 2 participants (300 mg group); all three events normalised within 5 days and were considered related to
 468 malaria.

469 **FIGURE LEGENDS**


470 **Figure 1. Trial profile.** Eligible participants were enrolled in one of three cohorts. All
471 participants in cohort 1 were allocated the same dose of tafenoquine (300 mg). Participants in
472 cohorts 2 and 3 were randomized within each cohort to a dose group on the day of dosing
473 with tafenoquine (8 days following challenge with blood-stage *P. falciparum*). All
474 participants completed the study and were included in the analysis of study endpoints.

475 **Figure 2. Individual participant parasitaemia-time profiles.** Participants were inoculated
476 intravenously with *P. falciparum*-infected erythrocytes on day 0 and were administered a
477 single oral dose of 200 mg (A), 300 mg (B), 400 mg (C) or 600 mg (D) tafenoquine (TQ) on
478 day 8 (indicated by the vertical dotted line). Definitive antimalarial treatment with a standard
479 course of artemether-lumefantrine (A/L) was initiated in response to parasite regrowth or on
480 day 48±2 (indicated by the vertical dashed line). Parasitaemia was measured using qPCR
481 targeting the gene encoding *P. falciparum*18S rRNA.

482

483 **FIGURES**


484 **Figure 1.**



485

486

487 **Figure 2.**



488

489

490 **SUPPLEMENTARY MATERIAL**

- 491 • Figure S1. Individual participant plasma concentrations of tafenoquine and 5, 6-
492 orthoquinone over time per dose.
- 493 • Figure S2. Individual participant venous whole blood concentrations of tafenoquine
494 and 5, 6-orthoquinone over time per dose.
- 495 • Figure S3. Individual participant capillary whole blood concentrations of tafenoquine
496 and 5, 6-orthoquinone over time per dose.
- 497 • Figure S4. Cumulative amount of tafenoquine and 5, 6-orthoquinone excreted in the
498 urine for each participant over time per dose.
- 499 • Text S1. Pharmacokinetic/pharmacodynamic analysis extended methods.
- 500 • Figure S5. Schematic diagram of the population pharmacokinetic/pharmacodynamic
501 model of tafenoquine and 5, 6-orthoquinone.
- 502 • Table S1. Population parameter estimates of the final tafenoquine pharmacokinetic
503 model.
- 504 • Figure S6. Visual predictive checks of the population pharmacokinetic model of
505 tafenoquine and 5, 6-orthoquinone.
- 506 • Table S2. Population estimates of the final pharmacokinetic/pharmacodynamic model.
- 507 • Figure S7. Visual predictive checks of the population
508 pharmacokinetic/pharmacodynamic model of tafenoquine and 5, 6-orthoquinone.
- 509 • Table S3. Efficacy parameters based on population and individual estimates following
510 administration of single doses of tafenoquine succinate.
- 511 • Table S4. Corresponding tafenoquine population pharmacodynamic parameters in
512 different biological matrices.
- 513 • Figure S8. Simulated total parasite reduction ratio in a hypothetical patient population
514 following administration of different single doses of tafenoquine.

- 515 • Figure S9. Probability of adequate parasitological response within 42 days (APR_{42})
- 516 for different single doses of tafenoquine.
- 517 • Table S5. Incidence of adverse events related to tafenoquine.
- 518 • Figure S10. Individual participant hemoglobin-time profiles.
- 519 • Figure S11. Individual participant methemoglobin-time profiles.
- 520 • Figure S12. Correlation between blood methemoglobin exposure and tafenoquine and
- 521 5,6-orthoquinone exposure in whole blood and plasma.
- 522 • Figure S13. Correlation between maximum blood methemoglobin concentration and
- 523 maximum tafenoquine and 5,6-orthoquinone concentrations in whole blood and
- 524 plasma.
- 525 • Text S2. Participant eligibility criteria.

526